CA2801243C - Methods of treating restless legs syndrome - Google Patents
Methods of treating restless legs syndrome Download PDFInfo
- Publication number
- CA2801243C CA2801243C CA2801243A CA2801243A CA2801243C CA 2801243 C CA2801243 C CA 2801243C CA 2801243 A CA2801243 A CA 2801243A CA 2801243 A CA2801243 A CA 2801243A CA 2801243 C CA2801243 C CA 2801243C
- Authority
- CA
- Canada
- Prior art keywords
- enantiomer
- compound
- carbon atoms
- pharmaceutical composition
- predominates
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/827,529 US8623913B2 (en) | 2010-06-30 | 2010-06-30 | Methods for treating restless legs syndrome |
| US12/827,529 | 2010-06-30 | ||
| PCT/KR2011/004677 WO2012002688A2 (en) | 2010-06-30 | 2011-06-27 | Methods of treating restless legs syndrome |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2801243A1 CA2801243A1 (en) | 2012-01-05 |
| CA2801243C true CA2801243C (en) | 2019-01-15 |
Family
ID=45400169
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2801243A Expired - Fee Related CA2801243C (en) | 2010-06-30 | 2011-06-27 | Methods of treating restless legs syndrome |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8623913B2 (https=) |
| EP (1) | EP2588099B1 (https=) |
| JP (1) | JP5921539B2 (https=) |
| KR (1) | KR101785072B1 (https=) |
| CN (1) | CN103025326B (https=) |
| CA (1) | CA2801243C (https=) |
| ES (1) | ES2638074T3 (https=) |
| WO (1) | WO2012002688A2 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1890684B1 (en) | 2005-06-08 | 2013-08-14 | SK Biopharmaceuticals Co., Ltd. | Treatment of sleep-wake disorders |
| KR20120098578A (ko) | 2009-06-22 | 2012-09-05 | 에스케이바이오팜 주식회사 | 피로의 치료 또는 예방 방법 |
| EP2496227B1 (en) | 2009-11-06 | 2019-05-22 | SK Biopharmaceuticals Co., Ltd. | Methods for treating fibromyalgia syndrome |
| BR112012010670A2 (pt) | 2009-11-06 | 2016-04-12 | Sk Biopharmaceuticals Co Ltd | métodos para tratamento de distúrbio de défict de atenção/hiperatividade |
| US9610274B2 (en) | 2010-06-30 | 2017-04-04 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating bipolar disorder |
| GB201221329D0 (en) | 2012-11-27 | 2013-01-09 | Avexxin As | Dermatitis treatment |
| CA2905457A1 (en) | 2013-03-13 | 2014-10-09 | Aerial Biopharma, Llc | Treatment of cataplexy |
| CA2917702A1 (en) | 2013-07-18 | 2015-01-22 | Jazz Pharmaceuticals International Iii Limited | Treatment for obesity |
| US10888542B2 (en) | 2014-02-28 | 2021-01-12 | Sk Biopharmaceuticals Co., Ltd. | Aminocarbonylcarbamate compounds |
| TWI698415B (zh) | 2014-02-28 | 2020-07-11 | 南韓商愛思開生物製藥股份有限公司 | 胺基羰基胺基甲酸酯化合物 |
| GB201604316D0 (en) | 2016-03-14 | 2016-04-27 | Avexxin As | Combination therapy |
| US10195151B2 (en) | 2016-09-06 | 2019-02-05 | Jazz Pharmaceuticals International Iii Limited | Formulations of (R)-2-amino-3-phenylpropyl carbamate |
| MY197630A (en) | 2016-09-06 | 2023-06-29 | Sk Biopharmaceuticals Co Ltd | Solvate form of (r)-2-amino-3-phenylpropyl carbamate |
| EP3515422A1 (en) | 2016-09-21 | 2019-07-31 | Avexxin AS | Pharmaceutical composition |
| ES2964943T3 (es) | 2016-10-06 | 2024-04-10 | Axsome Malta Ltd | Compuestos de carbamoilfenilalaninol para uso médico |
| BR112019025286A2 (pt) | 2017-06-02 | 2020-06-23 | Jazz Pharmaceuticals Ireland Limited | Métodos e composições para tratamento de sonolência excessiva |
| JP7366002B2 (ja) | 2017-07-31 | 2023-10-20 | ジャズ ファーマシューティカルズ アイルランド リミテッド | カルバモイルフェニルアラニノール類縁体およびその使用 |
| US11283085B1 (en) | 2020-03-06 | 2022-03-22 | Bloom Energy Corporation | Low VOC ink compositions and methods of forming fuel cell system components using the same |
| US10940133B1 (en) | 2020-03-19 | 2021-03-09 | Jazz Pharmaceuticals Ireland Limited | Methods of providing solriamfetol therapy to subjects with impaired renal function |
| US11515543B1 (en) | 2020-06-03 | 2022-11-29 | Bloom Energy Corporation | Aqueous fuel cell system component ink compositions and methods of forming fuel cell system components using the same |
| KR20260033050A (ko) | 2023-06-29 | 2026-03-10 | 액섬 테라퓨틱스, 인크. | 수유 여성에게 솔리암페톨을 투여하는 방법 |
| US12201783B1 (en) * | 2023-09-05 | 2025-01-21 | Steven F Pichette | Use of blue-light filtering eyeglasses for treatment of restless legs syndrome |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100197892B1 (ko) | 1994-09-09 | 1999-06-15 | 남창우 | 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법 |
| US5756817C1 (en) | 1995-02-11 | 2001-04-17 | Sk Corp | O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same |
| KR0173862B1 (ko) | 1995-02-11 | 1999-04-01 | 조규향 | O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법 |
| IT1275903B1 (it) | 1995-03-14 | 1997-10-24 | Boehringer Ingelheim Italia | Esteri e ammidi della 1,4-piperidina disostituita |
| KR0173863B1 (ko) | 1995-04-10 | 1999-04-01 | 조규향 | 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법 |
| DK0873308T3 (da) | 1996-10-10 | 2002-04-22 | Sk Corp | O-Carbamoyl-phenylalaninol-forbindelser og deres farmaceutisk anvendelige salte |
| TW548103B (en) | 1997-07-11 | 2003-08-21 | Janssen Pharmaceutica Nv | Bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives |
| EP1076055B1 (en) | 1998-04-28 | 2004-11-24 | Dainippon Pharmaceutical Co., Ltd. | 1- (1-substituted-4-piperidinyl)methyl]-4-piperidine derivatives, process for producing the same, medicinal compositions containing the same and intermediates of these compounds |
| US20010029262A1 (en) | 1998-06-29 | 2001-10-11 | Sethi Kapil Dev | Method of treatment or prophylaxis |
| TW518218B (en) | 1999-05-27 | 2003-01-21 | Merck Patent Gmbh | Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders |
| US20010034320A1 (en) | 2000-01-18 | 2001-10-25 | Hans-Michael Brecht | NK1-receptor antagonists for treating restless legs syndrome |
| CA2433018A1 (en) | 2000-12-21 | 2002-06-27 | Joel C. Barrish | Thiazolyl inhibitors of tec family tyrosine kinases |
| PT1411917E (pt) * | 2001-02-27 | 2007-09-17 | Ortho Mcneil Pharm Inc | ''compostos carbamatos para utilização na prevenção ou tratamento de distúrbios do movimento'' |
| IL157593A0 (en) | 2001-02-27 | 2004-03-28 | Ortho Mcneil Pharm Inc | Carbamate compounds for use in the treatment of pain |
| WO2002080928A1 (en) | 2001-04-03 | 2002-10-17 | Merck & Co., Inc. | N-substituted nonaryl-heterocyclo amidyl nmda/nr2b antagonists |
| WO2002100352A2 (en) | 2001-06-12 | 2002-12-19 | Merck & Co., Inc. | Nr2b receptor antagonists for the treatment or prevention of migraines |
| US20040115263A1 (en) * | 2002-08-26 | 2004-06-17 | Robertson David W. | Use of bupropion for treating restless legs syndrome |
| MXPA05003065A (es) | 2002-09-20 | 2005-05-27 | Pfizer | Compuestos de piperidinil-imidazopiridina n-sustituidos como moduladores del receptor 5-ht4. |
| MXPA05011270A (es) | 2003-04-21 | 2006-01-24 | Pfizer | Compuestos de imidazopiridina que tienen actividad agonista del receptor 5-ht4 y actividad antagonista del receptor 5-ht3. |
| KR100738784B1 (ko) | 2003-09-03 | 2007-07-12 | 화이자 인코포레이티드 | 5-ｈｔ4 수용체 효능 활성을 갖는 벤즈이미다졸론 |
| EP1548011A1 (en) | 2003-12-23 | 2005-06-29 | Neuro3D | Benzo[1,4]diazepin-2-one derivatives as phosphodiesterase PDE2 inhibitors, preparation and therapeutic use thereof |
| WO2005092882A1 (en) | 2004-03-01 | 2005-10-06 | Pfizer Japan, Inc. | 4-amino-5-halogeno-benzamide derivatives as 5-ht4 receptor agonists for the treatment of gastrointestinal, cns, neurological and cardiovascular disorders |
| RU2007119648A (ru) | 2004-10-28 | 2008-12-10 | СК Холдингз Ко. | Способ лечения депрессии |
| ES2520015T3 (es) | 2005-04-08 | 2014-11-11 | Pfizer Products Inc. | [3.1.0]Heteroaril amidas bicíclicas como inhibidores de transporte de glicina de tipo 1 |
| US7598279B2 (en) | 2005-04-22 | 2009-10-06 | Sk Holdings Co., Ltd. | Neurotherapeutic azole compounds |
| EP1890684B1 (en) * | 2005-06-08 | 2013-08-14 | SK Biopharmaceuticals Co., Ltd. | Treatment of sleep-wake disorders |
| EP1754476A1 (en) | 2005-08-18 | 2007-02-21 | Schwarz Pharma Ag | Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia |
| BRPI0719275A2 (pt) * | 2006-10-13 | 2014-04-29 | Janssen Pharmaceutica Nv | Composições de carbamatos de fenil-alquil-amino |
| US7377267B2 (en) * | 2006-10-30 | 2008-05-27 | Ford Global Technologies, Llc | Injection strategy to maximize efficiency in gaseous engine |
| CN101317949A (zh) * | 2008-07-15 | 2008-12-10 | 洛阳梓生科技开发有限公司 | 一种补血调经养血柔肝胶囊的制作方法 |
| US8642772B2 (en) | 2008-10-14 | 2014-02-04 | Sk Biopharmaceuticals Co., Ltd. | Piperidine compounds, pharmaceutical composition comprising the same and its use |
| KR20120098578A (ko) | 2009-06-22 | 2012-09-05 | 에스케이바이오팜 주식회사 | 피로의 치료 또는 예방 방법 |
-
2010
- 2010-06-30 US US12/827,529 patent/US8623913B2/en active Active
-
2011
- 2011-06-27 ES ES11801094.1T patent/ES2638074T3/es active Active
- 2011-06-27 CN CN201180032680.XA patent/CN103025326B/zh active Active
- 2011-06-27 CA CA2801243A patent/CA2801243C/en not_active Expired - Fee Related
- 2011-06-27 JP JP2013518242A patent/JP5921539B2/ja active Active
- 2011-06-27 EP EP11801094.1A patent/EP2588099B1/en active Active
- 2011-06-27 KR KR1020127032127A patent/KR101785072B1/ko active Active
- 2011-06-27 WO PCT/KR2011/004677 patent/WO2012002688A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP2588099A2 (en) | 2013-05-08 |
| KR20130087384A (ko) | 2013-08-06 |
| US8623913B2 (en) | 2014-01-07 |
| EP2588099A4 (en) | 2013-12-25 |
| WO2012002688A3 (en) | 2012-04-26 |
| JP2013531008A (ja) | 2013-08-01 |
| ES2638074T3 (es) | 2017-10-18 |
| WO2012002688A2 (en) | 2012-01-05 |
| CA2801243A1 (en) | 2012-01-05 |
| JP5921539B2 (ja) | 2016-05-24 |
| US20120004301A1 (en) | 2012-01-05 |
| EP2588099B1 (en) | 2017-05-24 |
| CN103025326A (zh) | 2013-04-03 |
| KR101785072B1 (ko) | 2017-10-12 |
| CN103025326B (zh) | 2015-07-29 |
| HK1178796A1 (en) | 2013-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2801243C (en) | Methods of treating restless legs syndrome | |
| US20240376045A1 (en) | Methods for treating attention-deficit/hyperactivity disorder | |
| US9688620B2 (en) | Methods for treating fibromyalgia syndrome | |
| AU2011272156B2 (en) | Methods for treating bipolar disorder | |
| HK1178796B (en) | Methods of treating restless legs syndrome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20160225 |
|
| MKLA | Lapsed |
Effective date: 20220301 |
|
| MKLA | Lapsed |
Effective date: 20200831 |